Showing 1321-1330 of 1635 results for "".
- EyeCheq adds Jai G. Parekh, MD, to its Executive Teamhttps://modernod.com/news/eyecheq-adds-jai-g-parekh-md-mba-to-its-executive-team/2481428/EyeCheq, the developer of a fully autonomous eye screening platform using artificial intelligence (AI), announced that Jai G. Parekh, MD, FAAO, has been named Executive Vice-President and Chief Innovation Officer. Dr. Parekh, a dual-train
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Eyenovia Announces Development Collaboration with Formosa Pharmaceuticalshttps://modernod.com/news/eyenovia-announces-development-collaboration-with-formosa-pharmaceuticals/2481412/Eyenovia announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals that seeks to combine Eyenovia’s Optejet dispensing technology with Formosa’s APNT nanoparticle formulation platform for the potential develop
- Researchers Identify Potential Cause of Keratoconushttps://modernod.com/news/researchers-identify-potential-cause-of-keratoconus/2481402/Researchers at the University of North Texas Health Science Center are the first to characterize extracellular vesicles (EVs) in the tears of patients with keratoconus, according to an National Eye Institute news release. Dimitrios Karamichos, PhD, executive director of the North
- Study: Early Anti-VEGF Treatment of Diabetic Retinopathy Slows Progression but Yields No Benefit to Visual Acuityhttps://modernod.com/news/study-early-anti-vegf-treatment-of-diabetic-retinopathy-slows-progression-but-yields-no-benefit-to-visual-acuity/2481399/While early treatment of diabetes-related eye disease slowed progression to severe disease, it did not improve visual acuity compared with treating more severe disease once it developed, according to a clinical study from the DRCR Retina Network. The study was funded by the National Eye Institute
- FDA Clears IND Application for Huidagene Therapeutics' RPE65 Mutation-Associated Inherited Retinal Dystrophieshttps://modernod.com/news/fda-clears-ind-application-for-huidagene-therapeutics-rpe65-mutation-associated-inherited-retinal-dystrophies/2481373/HuidaGene Therapeutics announced that the FDA has cleared its investigational new drug (IND) application for the planned multi-national clinical trial of HG004 for the treatment of patients suffering from RPE65 mutation-associated inherited retinal dystrophies.
- Study: Zebrafish Model Helps Explain Eye Developmenthttps://modernod.com/news/study-zebrafish-model-helps-explain-eye-development/2481352/Scientists at the National Eye Institute (NEI) have developed a zebrafish model of NEDBEH—a rare genetic disorder that can cause coloboma, where parts of the eye are missing due to developmental defects. The model provides a new tool for understanding the eye's embryonic developmen
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primateshttps://modernod.com/news/aviceda-announces-successful-completion-of-key-ind-toxicity-milestone-with-favorable-safety-profile-in-non-human-primates/2481280/Aviceda Therapeutics announced completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies in two species (total of 80 animals) as agreed upon in discussions with the FDA. Cambridge, Massachusetts-based Aviceda, has developed a proprietary nano-technology HALOS&
- Study: Vision Impairment is Associated with as Many as 100,000 US Dementia Caseshttps://modernod.com/news/study-vision-impairment-is-associated-with-as-many-as-100000-us-dementia-cases/2481238/Up to 100,000 US dementia cases could have potentially been prevented with improved eye care, according to a National Institute on Aging (NIA)-funded study published in JAMA Neurology. While the search for breakthrough drugs or interventions that could be treatments f